Research & Treatment News articles

First-Line Treatment Approved for Stage IV Colorectal Cancer

There is new first-line treatment (standard of care to start treatment) giving as many as 60% of the stage IV colorectal cancer patients more options for treatment. Previously, most stage IV patients undergoing chemotherapy would be recommended to go on FOLFOX and bevacizumab (Avastin). Patients would receive this first set of drugs (called first-line) and if the cancer continued to grow, then other treatment options would be explored. Recently, the FDA approved an additional drug to be used as a first-line option for some stage IV patients. But this is for a specific set of patients based on their tumor gene type, known as biomarker. The new targeted therapy panitumumab

Webinar Wrap-Up – Family First – Genetic Syndromes by Heather Hampel

Patients, caregivers and family members use our webinars each month to learn more about the battle against colorectal cancer and find the news they need to stay informed. At Fight Colorectal Cancer, we believe that education empowers those affected by colorectal cancer to take control of their lives. Below is Q&A with Heather Hampel, our presenter of the webinar “Family First: What You Need To Know About Genetic Testing, Family History & Colorectal Cancer.“   Q&A with Heather Q: I would like to know when my children need to start getting colonoscopies. (They’re 32 and 25). Also would like to know if there is any connection, at all, between an astrocytoma brain tumor and

ASCO-booths

Andi’s Highlights on ASCO 2014

by Andi Dwyer, Director of Health Promotion, Fight Colorectal Cancer Working in the cancer prevention and survivorship field for nearly ten years, I was elated to attend my first ASCO.  However, nothing prepared me for the 35,000 people from throughout the world, gathered to unveil the latest in ‘all things’ cancer.  I came in with a notion this was a research conference; I discovered, it was so much more. Policy, advocacy, pharmaceutical, basic research and clinical/medical science from the entire planet, collided into a single city for a solid four days.  It was intense and complete with opportunity and challenge but none-the-less, a guide for this year and beyond. ASCO info about Biomarkers

Greys Anatomy Farting Episode – It’s True!

Recently, the colorectal cancer community received a ‘nod’ from the widely popular ABC show Grey’s Anatomy. In the episode a young woman who’d survived cancer struggled to control her flatulence and bowel movements – many recaps over the past few weeks have even referred to her as “The Farter.” It’s raised many questions within the community – namely, is this true? Do you pass gas a lot more once you’ve had colorectal surgery? To firm this up, we asked Dr. James Waller, a colorectal surgeon from Evansville, Indiana to talk to us about farting. Dr. Waller provides young adult survivors at The Colon Club with answers to some of these obscure questions on a

Flo-AACR

FLO’S WORDS OF WISDOM : THE ANNUAL AACR MEETING AND BEING A RAT

I had the great opportunity to attend this year’s American Association of Cancer Research (AACR) meeting in San Diego and what an experience it was!  I arrived on Saturday morning and the first thing I did was try to acquaint myself with the hotel, as there was a satellite registration for attendees in the lobby – the very huge, spacious, long lobby!  There were over 20,000 attendees in multiple hotels throughout the area. We were fortunate to be in the conference hotel adjacent to the convention center. Breakout Groups In the afternoon we had lunch and the opening meeting of our advocacy groups. Our groups consisted of six teams with

david-wicks-donald-payne-jr

2014 Award Winners

Each March at Call-on Congress, Fight Colorectal Cancer recognizes individuals who exemplify what our organization is all about. These people are not only advocates – they’re champions. Each of them offers their experience and passion to further the cause. This year’s 2014 Award Winners set the bar high. Advocate of the Year – Gordon Cole A survivor of stage IV colorectal cancer since 2003, Gordon Cole is an inspiration. As a hands-on patient, he’s actively monitored his own treatment (which consists of multiple surgeries, radiation, chemotherapy and several clinical trials.) As an advocate, he’s pushed for better policy and research funding. His constant voice has helped us raise colorectal cancer

fight-crc-lisa-fund-awards-2014

7th Lisa Fund Grant Awarded to Dr. Ho-Chou Tu

Fight Colorectal Cancer is excited to announce that Dr. Ho-Chou Tu received our 7th Lisa Fund Fellowship Grant – a $50,000 award given to a late-stage colorectal cancer researcher. This award is distributed through the Lisa Fund in partnership with American Association of Cancer Research (AACR.) Dr. Tu is a research fellow at the Children’s Hospital in Boston. She plans to use the award to determine the relationship between the Lin28A/B gene and colon cancer progression and prognosis. She hopes that her research will lead to predictive biomarkers for prognosis of colon cancer and a potential therapeutic target aimed to reduce colon cancer progression. Dr. Tu, a native of Taiwan,

Clarification: Panel Approves Cologuard (not the FDA)

Fight Colorectal Cancer submitted public comments to the FDA last week regarding new colorectal cancer screening tests, including Cologuard by Exact Sciences and Epi proColon by epigenomics. (Read comments here.) Cologuard Update As a result of the advisory committee meeting, an FDA panel voted 10-0 to recommend that the FDA approve Cologuard. Cologuard is a stool-based screening test that looks for DNA in a patient’s stool that may detect genetic changes associated with cancer cells in the colon or rectum. A positive result from this test would lead patients to diagnostic colonoscopy. In this case, as we commented on new screening technologies we kept the following considerations in mind: 1)

Comments on New DNA & Stool-Based Screening Tests to FDA

This week Fight Colorectal Cancer is providing comments to the FDA as they consider two new screening technologies for colorectal cancer. Below are our opinions and recommendations presented to the Molecular and Clinical Genetics Panel as part of the Medical Devices Advisory Committee. Background: This week, the Food & Drug Administration (FDA) is hosting an advisory committee meeting with many stakeholders that have an interest in two new potential screening technologies, Epi proColon (by Epigenomics) and Cologuard (by Exact Sciences). Kim Ryan, our Director of Patient Information Services and advocate Marcia Mullins are attending to provide comments as the FDA considers these two new screening technologies.   About Epi proColon & Cologuard

New Screening Tool: PillCam COLON

by gastroenterologist and Fight Colorectal Cancer board member Indran Indrakrishnan M.D.  PillCam® COLON  is a new technology to evaluate the colon for polyps. The FDA recently gave clearance for the PillCam® COLON to be used in patients following an incomplete colonoscopy. Read more here. The basic concept of capsule endoscopy has been in practice for nearly 10 years for evaluating the small bowel. The PillCam® COLON relies on a thorough, high-quality bowel preparation for accuracy, just like colonoscopy, and serves as a new screening tool complementary to a colonoscopy. Uses of the New Technology This new technology will be particularly useful for: 1. Patients who are not willing to undergo an invasive procedure 2. The occasional

Top